Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Would you feel comfortable doing high tangents with ultra-hypofractionation?
What is your preferred method of surveillance after mastectomy?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Do you recommend high ozonated oil for radiation dermatitis?
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
Have the breast surgeons at your institution adopted the SOUND trial into their clinical practice?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Would you offer prone APBI with IMRT/VMAT?
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
